返回 
加入收藏
阿利西尤单抗联合阿托伐他汀对急性冠脉综合征患者PCI术后临床疗效和安全性的影响
x
请在关注微信后，向客服人员索取文件
| 篇名： | 阿利西尤单抗联合阿托伐他汀对急性冠脉综合征患者PCI术后临床疗效和安全性的影响 |
| TITLE： | Effects of alirocumab combined with atorvastatin on clinical efficacy and safety in patients with acute coronary syndrome after PCI |
| 摘要： | 目的 探讨阿利西尤单抗联合阿托伐他汀对急性冠脉综合征（ACS）患者接受经皮冠脉介入术（PCI）后临床疗效和安全性的影响。方法将2021年1月至2023年12月我院收治的207例患有ACS并接受PCI治疗者，按随机数字表法分为阿利西尤单抗组、依折麦布组和对照组，每组69例。所有患者均在PCI术后接受常规预防血栓、降压等治疗。在此基础上，对照组患者采用阿托伐他汀（20mg/次，每天1次）治疗；依折麦布组患者采用依折麦布（10mg/次，每天1次）+阿托伐他汀（20mg/次，每天1次）治疗；阿利西尤单抗组患者采用阿利西尤单抗（75mg/次，每2周1次）+阿托伐他汀（20mg/次，每天1次）治疗。3组患者均治疗8周，治疗后再随访6个月。比较3组患者治疗前后的心功能指标、脂代谢指标水平以及随访期间的主要心血管不良事件（MACE）及其他药物不良反应（ADR）的发生情况。结果治疗8周后，3组患者的心功能和脂代谢指标水平均较同组治疗前显著改善（P＜0.05）；与对照组和依折麦布组相比，阿利西尤单抗组患者的左室射血分数显著升高，左室舒张末期内径（LVEDD）显著缩短（P＜0.05）；与对照组相比，依折麦布组患者的LVEDD显著缩短（P＜0.05），阿利西尤单抗组和依折麦布组患者的总胆固醇、甘油三酯和低密度脂蛋白胆固醇水平均显著降低（P＜0.05）。随访期间，3组患者的MACE总发生率和头痛、腹痛等其他ADR总发生率比较，差异均无统计学意义（P＞0.05）。结论阿利西尤单抗联合阿托伐他汀可显著改善PCI术后ACS患者的心功能，调节其脂代谢指标水平，且不会增加MACE或其他ADR的发生风险。 |
| ABSTRACT： | OBJECTIVE To investigate the effects of alirocumab combined with atorvastatin on clinical efficacy and safety of patients with acute coronary syndrome （ACS） who underwent percutaneous coronary intervention （PCI）. METHODS A total of 207 patients with ACS who underwent PCI in our hospital from January 2021 to December 2023 were randomly divided into alirocumab group， ezetimibe group and control group， with 69 cases in each group. All patients received routine thrombosis prevention and antihypertensive treatment after PCI. On this basis， patients in the control group were treated with atorvastatin （20 mg/time， once a day）； patients in the ezetimibe group were treated with ezetimibe （10 mg/time， once a day） + atorvastatin （20 mg/time， once a day）； patients in the alirocumab group were treated with alirocumab （75 mg/time， once every 2 weeks） + atorvastatin （20 mg/time， once a day）. All patients in the three groups were treated for 8 weeks and followed up for another 6 months after treatment. The levels of cardiac function and lipid metabolism indices before and after treatment， as well as the occurrence of major adverse cardiovascular event （MACE） and other adverse drug reaction （ADR） during the follow-up period were compared among the three groups. RESULTS After treatment for 8 weeks， the levels of cardiac function and lipid metabolism indices in the three groups were significantly improved compared with those before treatment （P＜0.05）. Compared with the control group and ezetimibe group， the left ventricular ejection fraction in the alirocumab group was significantly increased， and the left ventricular end-diastolic diameter （LVEDD） was significantly shortened （P＜0.05）. Compared with control group， LVEDD of ezetimibe group was significantly shortened （P＜0.05）， the levels of total cholesterol， triglyceride and low-density lipoprotein cholesterol in the alirocumab group and ezetimibe group were significantly decreased （P＜0.05）. During the follow-up period， there was no significant difference in the total incidence of MACE and the total incidence of other ADR such as headache and abdominal pain among the three groups （P＞0.05）. CONCLUSIONS Alirocumab combined with atorvastatin can significantly improve cardiac function and regulate lipid metabolism indices in patients with ACS after PCI without increasing the risk of MACE or other ADR. |
| 期刊： | 2025年第36卷第10期 |
| 作者： | 郝翠君；王蕊；马逸平；张雪萍；刘亚男；秦少强 |
| AUTHORS： | HAO Cuijun，WANG Rui，MA Yiping，ZHANG Xueping，LIU Yanan，QIN Shaoqiang |
| 关键字： | 阿利西尤单抗；阿托伐他汀；急性冠脉综合征；经皮冠脉介入术；临床疗效；安全性；心功能；脂代谢；主要心血管不良事件 |
| KEYWORDS： | alirocumab； atorvastatin； acute coronary syndrome； percutaneous coronary intervention； clinical efficacy； safety； |
| 阅读数： | 2 次 |
| 本月下载数： | 0 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
